GeoVax is a Georgia-based clinical-stage biotechnology company with a focus on researching and developing vaccines for illnesses including HIV, Ebola, HBV, HPV, and for cancer immunotherapy. The company designs its programs around a novel platform that integrates its recombinant Modified Vaccinia Ankara (MVA) vector technology with antigen design and manufacturing technologies.
In 2020, the company partnered with BravoVax, a Chinese pharmaceutical testing and manufacturing company. GeoVax had been conducting research for a vaccine for COVID-19 and developed three vaccine candidates. The company stated that it would narrow it down to one candidate and upon approval, commence animal studies with the vaccine.
Timeline
Funding rounds
People
David Dodd
CEO
Harriet L. Robinson
Co-Founder
Further reading
GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program
GeoVax, Inc.
Web
March 18, 2020
Testing to begin in metro Atlanta for COVID-19 vaccines
Web
March 31, 2020
Documentaries, videos and podcasts
Cobb company to soon begin testing possible vaccines for COVID-19